Moderna’s mRNA flu vaccine set for FDA review after positive AdCom - Pharmaceutical Technology

The panel unanimously said that the benefits of Moderna's mRNA jab outweigh its risks in preventing influenza in certain age groups. The panel unanimously said that the benefits of Moderna's mRNA jab outweigh its risks in preventing influenza in certain age groups. Shares in Moderna rose 3.5% to $63.96 at market open on 18 June following the vote. Credit: Lutsenko_Oleksandr/Shutterstock.com. Moderna’s mRNA vaccine for influenza prevention has passed a US Food and Drug Administration (FDA) Advisory Committee (AdCom) meeting, meaning the company has successfully navigated a volatile backdrop with the modality in the US. The FDA panel of experts discussed…

Source: Pharmaceutical Technology